Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus

Ann Oncol. 2013 Feb;24(2):270-272. doi: 10.1093/annonc/mds641.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Castration
  • Clinical Trials as Topic
  • Docetaxel
  • Humans
  • Male
  • Molecular Targeted Therapy
  • Prostatic Neoplasms / drug therapy*
  • Taxoids / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Taxoids
  • Docetaxel
  • intetumumab